Collaborative Advancement of Recovery Excellence
Translating science to service, powered by Gloo
Nearly half of behavioral health executives polled said they see the recovery and wellness of their clients declining in the context of COVID-19, according to the first Weekly Director Poll published by the Psychiatry & Behavioral Health Learning Network and Gloo.
A Johns Hopkins study has found that individuals in recovery who received a supplemental $8 per hour in their wages were more likely to provide drug-free urine samples and maintain steady employment.
In a study of mice, a buprenorphine analog was found to be more effective at activating receptors that prevent cocaine relapse without increasing addiction potential, according to a Science Magazine report.
The Weekly Director Poll, part of the State of the Industry This Week initiative, will provide behavioral healthcare industry executives insights on how their peers are addressing issues of team/staff health, operations, service delivery and more.
A long-term safety study of extended-release buprenorphine illustrates a safety profile comparable to that of the sublingual version of the drug.
A longer duration of treatment with the injectable formulation of buprenorphine for opioid use disorder was associated with more favorable abstinence outcomes in a newly published study.
Coping During COVID-19
A survey from the American Psychiatric Association provides a glimpse into the mental well-being of Americans amid the COVID-19 pandemic.
Sexual minority women appear to be at greater risk of substance use-related problems than heterosexual women, but major gaps remain in research, a review suggests.
Nineteen projects to improve access to treatment have received funding in a Foundation for Opioid Response Efforts round that attracted nearly 450 proposals.
The most comprehensive review yet of 12-Step based approaches to treating alcohol use disorder shows major benefits from 12-Step Facilitation.